이식형 제세동기(ICD) 시장 : 디바이스 유형별, 제품 유형, 치료법별, 이식 유형별, 적응증별, 용도별 - 세계 시장 예측(2026-2032년)

The Implantable Cardioverter Defibrillators Market is projected to grow by USD 7.66 billion at a CAGR of 6.28% by 2032.

Implantable Cardioverter Defibrillators Market Overview

Implantable cardioverter defibrillators (ICDs) remain a cornerstone therapy for preventing sudden cardiac death in patients at high risk of life-threatening ventricular tachyarrhythmias. The clinical rationale is well established: cardiovascular disease is the world's leading cause of death, with the World Health Organization reporting 17.9 million cardiovascular deaths in 2019, and major cardiology guidelines continue to support ICD therapy for eligible patients with reduced ejection fraction, prior cardiac arrest, or documented ventricular arrhythmias.

The implantable cardioverter defibrillators market is being shaped by an aging population, higher survival after myocardial infarction and heart failure, expanding electrophysiology capabilities, and stronger use of remote cardiac monitoring. Demand is concentrated across transvenous ICDs, subcutaneous ICDs, cardiac resynchronization therapy defibrillators, leads, pulse generators, and device management platforms, making the sector strategically important for medtech manufacturers, hospitals, payers, and digital health partners.

Transformative Shifts in the ICD Landscape

The ICD landscape is moving from device-centric intervention toward connected, outcomes-driven cardiac care. Remote monitoring, longer battery life, MRI-conditional labeling, improved lead design, and programming strategies that reduce inappropriate shocks are changing how clinicians manage patients after implantation. These advances support better continuity of care while reducing avoidable clinic burden.

Another major shift is the rising preference for personalized device selection. Transvenous ICDs remain widely used where pacing and defibrillation are both required, while subcutaneous ICDs are increasingly relevant for patients who need defibrillation without chronic intravascular leads. Health systems are also emphasizing shared decision-making, guideline adherence, infection prevention, and lifecycle cost management as ICD adoption expands.

Cumulative Impact of Artificial Intelligence on ICDs

Artificial intelligence is beginning to influence the ICD ecosystem through risk stratification, arrhythmia detection, remote monitoring triage, and predictive maintenance. AI-supported analytics can help clinicians prioritize alerts, identify changes in heart failure status, and interpret large volumes of rhythm and device data generated by connected cardiac implantable electronic devices.

The cumulative impact of AI is expected to be operational as much as clinical. Hospitals and device clinics face growing workloads from remote monitoring transmissions, and algorithmic triage can help focus clinician attention on actionable events. However, AI adoption must remain aligned with regulatory expectations, cybersecurity safeguards, transparent validation, and clinician oversight because ICD therapy decisions carry high patient-safety implications.

Key Regional Insights Across the ICD Market

North America continues to lead ICD adoption because of established electrophysiology networks, broad guideline awareness, advanced reimbursement pathways, and high prevalence of heart failure and ischemic heart disease. The United States anchors regional demand through large procedure volumes, regulated device innovation, and strong remote monitoring penetration, while Canada benefits from organized cardiac care pathways and public reimbursement structures.

Europe shows mature ICD utilization supported by European Society of Cardiology guidelines, national device registries, and strong hospital infrastructure in countries such as Germany, France, Italy, Spain, and the United Kingdom. Asia-Pacific is the fastest-evolving opportunity as China, India, Japan, South Korea, Australia, and ASEAN health systems expand access to electrophysiology services, although reimbursement variability, specialist distribution, and affordability remain key constraints.

Latin America, the Middle East, and Africa present uneven but meaningful development potential. Brazil and Mexico lead Latin American adoption through tertiary cardiac centers and expanding private-sector capability, while the Middle East is supported by specialty hospital investment, particularly across Gulf health systems. In Africa, demand is concentrated in major urban hospitals where device affordability, electrophysiology specialist availability, supply continuity, and post-implant follow-up infrastructure determine access.

Key Group Insights for ICD Commercial Strategy

The G7 represents the most commercially mature ICD environment, with advanced regulatory systems, established reimbursement, higher availability of electrophysiology specialists, and broad adoption of guideline-directed cardiovascular care. NATO members overlap heavily with developed North American and European markets, where procurement standards, cybersecurity expectations, supply-chain resilience, and secure remote monitoring infrastructure are increasingly relevant for connected ICD platforms.

The European Union is important for harmonized medical device oversight under the EU Medical Device Regulation and for cross-country evidence generation through registries, post-market surveillance, and health technology assessment. BRICS economies, led by China, India, and Brazil, represent major long-term adoption potential because of large cardiovascular disease burdens, expanding hospital networks, and rising access to specialty cardiovascular care, while Russia and South Africa remain influenced by regional procurement capacity and tertiary-care concentration.

ASEAN is gaining attention as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines scale cardiac services at different speeds, with access shaped by public reimbursement, private hospital investment, and specialist availability. The GCC is distinguished by high healthcare investment, specialty hospital development, and demand for advanced cardiac technologies, although local workforce development, referral pathways, and long-term follow-up models remain essential for sustainable ICD care.

Key Country Insights for ICD Adoption

The United States is the most influential ICD market, supported by clinical guideline adoption, Medicare coverage, strong private payer participation, and a large base of electrophysiology centers. Canada maintains steady demand through provincial healthcare systems and organized cardiac referral pathways, while Mexico and Brazil are key Latin American countries where public-private access differences, tertiary hospital concentration, and affordability shape implant rates.

In Europe, Germany is a major ICD and cardiac resynchronization therapy defibrillator market because of strong hospital infrastructure, procedural capacity, and established reimbursement mechanisms. France, Italy, Spain, and the United Kingdom contribute stable demand through national health systems and guideline-based care, while Russia's opportunity depends on regional cardiac center capacity, procurement conditions, and access to specialized electrophysiology services.

China and India are central to Asia-Pacific ICD adoption because of large patient populations, high cardiovascular disease burden, and expanding cardiovascular programs, but reimbursement depth, affordability, and specialist distribution remain decisive. Japan, South Korea, and Australia show more mature adoption patterns, supported by advanced hospitals, aging demographics, established regulatory frameworks, and wider use of remote cardiac monitoring in follow-up care.

Actionable Recommendations for ICD Industry Leaders

Industry leaders should prioritize evidence-based differentiation by demonstrating reductions in inappropriate shocks, infection risk, lead complications, alert burden, and total cost of care. Product roadmaps should emphasize remote monitoring interoperability, cybersecurity-by-design, battery longevity, MRI compatibility, device miniaturization, and patient-friendly follow-up workflows.

Commercial teams should align market access strategies with local reimbursement and health technology assessment requirements. In emerging markets, partnerships with tertiary hospitals, clinician training programs, financing models, referral network development, and post-implant monitoring infrastructure can expand access while protecting clinical outcomes.

Manufacturers should also invest in AI governance, real-world evidence generation, and registry collaboration. Transparent validation of algorithms, inclusive datasets, secure data handling, and clinician-controlled decision support will be critical for building trust among regulators, physicians, payers, and patients.

Research Methodology for ICD Market Insights

This executive summary is based on secondary research from authoritative clinical, regulatory, and public health sources, including cardiology society guidelines, public health statistics, medical device regulatory information, peer-reviewed literature, device safety communications, and hospital care pathway evidence. The analysis emphasizes verified factors affecting ICD demand, including cardiovascular disease burden, heart failure prevalence, reimbursement, technology adoption, electrophysiology infrastructure, and remote monitoring readiness.

Market interpretation was developed through triangulation across clinical practice trends, regional healthcare capacity, regulatory environments, adoption barriers, and digital health implementation factors. The methodology excludes unsupported market sizing claims and focuses on defensible insights relevant to implantable cardioverter defibrillator manufacturers, healthcare providers, payers, investors, procurement stakeholders, and digital health participants.

Conclusion: The Future of ICD Market Growth

The ICD market is entering a more connected, data-driven phase in which device performance, remote monitoring, AI-enabled triage, cybersecurity, and patient access will define competitive advantage. Clinical need remains durable because sudden cardiac death prevention is a high-priority component of modern cardiovascular care.

Organizations that combine strong clinical evidence, reliable device engineering, secure digital platforms, and localized access strategies will be best positioned to capture growth. As healthcare systems seek better outcomes and efficient follow-up, ICD innovation will increasingly be measured not only by implant activity but also by long-term patient safety, workflow efficiency, equitable access, and value-based care impact.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Implantable Cardioverter Defibrillators Market, by Device Type

• 7.1. Subcutaneous ICDs
• 7.2. Transvenous ICDs

8. Implantable Cardioverter Defibrillators Market, by Product Type

• 8.1. Pulse Generator
• 8.2. Electrodes
• 8.3. External Accessories

9. Implantable Cardioverter Defibrillators Market, by Therapy Type

• 9.1. Defibrillation Therapy
• 9.2. Cardioversion Therapy
• 9.3. Anti-Tachycardia Pacing
• 9.4. Cardiac Resynchronization Therapy

10. Implantable Cardioverter Defibrillators Market, by Implantation Type

• 10.1. Single Lead Implantation
• 10.2. Dual Lead Implantation
• 10.3. Triple Lead Implantation

11. Implantable Cardioverter Defibrillators Market, by Indication

• 11.1. Primary Prevention
• 11.2. Secondary Prevention

12. Implantable Cardioverter Defibrillators Market, by Application

• 12.1. Ventricular Tachycardia
• 12.2. Ventricular Fibrillation
• 12.3. Heart Failure
• 12.4. Sudden Cardiac Arrest (SCA) Prevention

13. Implantable Cardioverter Defibrillators Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Implantable Cardioverter Defibrillators Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Implantable Cardioverter Defibrillators Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. Angiplast Pvt Ltd.
• 17.3. Atrium Medical, Inc.
• 17.4. B. Braun Melsungen AG
• 17.5. Becton, Dickinson and Company
• 17.6. BIOTRONIK SE & Co. KG
• 17.7. Boston Scientific Corporation
• 17.8. Cardinal Health, Inc.
• 17.9. ConMed Corporation
• 17.10. ConvaTec Group PLC
• 17.11. Cook Medical Inc.
• 17.12. Fresenius Medical Care AG & Co. KGaA
• 17.13. Getinge AB
• 17.14. LivaNova PLC
• 17.15. Medtronic plc
• 17.16. Merit Medical Systems, Inc.
• 17.17. MicroPort Scientific Corporation
• 17.18. Olympus Corporation
• 17.19. Stryker Corporation
• 17.20. Teleflex Incorporated
• 17.21. ZOLL Medical Corporation